Attendee search 

The Innovation Forum is an accelerator for healthcare ventures. It is supported by a global grassroots network of over 10,000 innovators who seek to improve human health and wellbeing by translating cutting-edge science into innovative products and services. We focus on the future and the evolution of today’s technologies, which range from the nascent stage to the cusp of commercial application.

University

UK Pharmaceutical

Charnwood Molecular is an award-winning, UK-based CRO, which has been providing expert synthetic chemistry support for over 20 years. At Charnwood Molecular, we work with clients of all shapes, sizes and global standing. These range across a variety of sectors, from virtual start-ups to established global agrochemical, materials chemistry, diagnostics, biotechnology and pharmaceutical companies. All of our clients benefit from our proactive and open approach, geared towards rapidly advancing projects towards important key decision points and beyond.

Connexin Therapeutics Ltd. is a UK-based biopharmaceutical company specializing in the Discovery and development,, of drugs targeting connexins, initially for the prevention of vision loss and blindness associated with the eye disease known as glaucoma. While there are a variety of glaucoma subtypes, a common hallmark is the progressive loss of vision due to the gradual cell death in the retina and optic nerve triggered by elevated intraocular pressure. Many drugs are available to reduce intraocular pressure, yet none have been shown to directly protect cells in the retina or optic nerve, and hence prevent them from dying. Thus, vision loss inevitably occurs, even in well-treated patients, and severe vision impairment remains common in these patients.
Connexin Therapeutics raised ~£150,000 in Seed financing in early 2019. These funds are being used to synthesize and test novel small molecules in animal models of glaucoma. Selected results from these studies are presented in this document. These compounds are based on a molecule which has already demonstrated efficacy in mouse models of glaucoma. Thus, these data supplement and extend the work already published.
We are currently raising ~£2,000,000 to expand our synthesis and optimize our lead compounds. After ~8-10 quarters of work we anticipate having a library of patentable compounds which are highly selective for our target, backed by cell and animal data. We may also have a second compound which inhibits a different retinal target for a different set of conditions. Future financing rounds will take one or both leads into formulation development, safety studies, and clinical trials, while also fueling our expansion into other indications with this same mechanism of action.

TusPark UK is a science and technology service corporation with an investment arm as a venture capital and private equity group fund. TusPark UK has invested £250M+ in Cambridge since 2018 (e.g. the landmark joint venture with the Trinity College to develop and operate TusPark Cambridge Science Park), and its investment portfolio spans in the era of life science/healthcare, digital technologies (big data, AI and IoT, etc.), new material, and environmental & new energy, with a unique model of "Incubation + Investment + M&As".

医疗专业精品投行